

## **URGENT! EMERGING THERAPEUTIC ISSUES COMMUNICATION**

On May 6, 2008, a truck containing Johnson & Johnson's Remicade<sup>®</sup> (infliximab), Procrit<sup>®</sup> (epoetin alfa) and Doxil<sup>®</sup> (doxorubicin liposomal inj.) was stolen. The company is recalling these products due to concerns that the supply could be reintroduced into the market and its safety can no longer be assured. As a precaution, the company is taking the all lots of Remicade, Procrit and Doxil with the same lot numbers as the stolen products off of the market. This will make it easier to identify the stolen drug if it does reenter the market. All other lots are considered safe to use.

Of the stolen drugs, only Procrit is self administered. The recalled lots of Procrit include:

Procrit (10,000 U/ml) single use vials D091534 07/2010  
Procrit (20,000 U/ml) multidose vials P113612 09/2010  
Procrit (40,000 U/ml) single use vials P106803 06/2010

More information about the recall can be found at:

[http://www.procrit.com/procrit/assets/PR\\_15MAY2008.pdf](http://www.procrit.com/procrit/assets/PR_15MAY2008.pdf)

### **Express Scripts response:**

- In an effort to inform members of this recall, we have identified members who have received a prescription for Procrit since May 7, 2008. A communication summarizing the information provided by the manufacturer will be sent to these members.
- The above communications will be distributed for those clients enrolled in the member portions of the Emerging Therapeutic Issues Patient Safety Program., respectively.

If we can answer any questions, or if you are interested in the Emerging Therapeutic Issues Program and are currently not enrolled, please contact your Clinical Program Manager at your convenience.